Adipose deficit repair
Where tissue has lost its natural fat cushion—through injury, surgical defect, or structural adipose loss—Liposana restores human adipose allograft to support complete repair rather than relying on synthetic fillers or autologous fat harvest.
No synthetic agents
Liposana is processed without cross-linking agents, synthetic scaffolds, or foreign materials. It maintains the biocompatibility and structural properties of native adipose tissue through Britecyte's allogeneic processing pathway.
Ready to use workflow
As an off-the-shelf allograft, Liposana eliminates the need for same-patient fat harvest. It is supplied in 1.5 cc vials—a processed, immunogenicity-resolved product ready for implantation in clinical settings where structural cushioning is required.
Shared Britecyte platform
Liposana and Lipoderma share the same foundational allogeneic adipose technology—patent-protected processing that resolves immunogenicity while preserving native matrix architecture. Liposana addresses repair; Lipoderma addresses aesthetic restoration.